Patents Examined by Timothy R Rozof
  • Patent number: 11401255
    Abstract: The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 2, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Wolfdieter Springer, Fabienne C. Fiesel, Thomas R. Caulfield
  • Patent number: 11401264
    Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: August 2, 2022
    Assignee: Orizuru Therapeutics, Inc.
    Inventors: Yoshinori Yoshida, Kenji Miki, Akira Kaieda, Shigeru Kondo, Hiroshi Nara, Yoshinori Ikeura
  • Patent number: 11396518
    Abstract: Disclosed is an amorphous solid form of compound (S)—N-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrole-1-yl]acetamide.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: July 26, 2022
    Assignee: TIANJIN HEMAY PHARMACEUTICAL CO., LTD.
    Inventors: Donglei Zhang, Liyu Wang, Xingwen Li
  • Patent number: 11396527
    Abstract: Described are dual mass-spectrometry-cleavable cross-linkers that can be cleaved selectively using two differential tandem mass-spectrometric techniques such as collision induced dissociation (CID) or electron transfer dissociation (ETD), i.e., a dual cleavable crosslinking technology (DUCCT) cross-linker. When used to cross-link a macromolecule, such as a peptide, MS/MS fragmentation produces two signature complementary mass spectra of same cross-linked peptides, the analysis of which gives rise to high confidence in characterizing the structures of the cross-linked macromolecules as well as sites of interactions. Also described, are methods of making and using DUCCT cross-linkers.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: July 26, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Saiful Mahmud Chowdhury
  • Patent number: 11396510
    Abstract: The present invention relates to 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, which is useful as a GABA receptor modulator. In one embodiment, said compound is useful in the treatment of pain, neuropathic pain and/or itch.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: July 26, 2022
    Assignee: Saniona A/S
    Inventors: Janus S. Larsen, Dipak Amrutkar, Thomas Amos Jacobsen, Tino Dyhring, Karin Sandager Nielsen
  • Patent number: 11389543
    Abstract: Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 19, 2022
    Assignee: Seagen Inc.
    Inventors: Kun-Liang Wu, Qingwu Jin, Wendel Doubleday
  • Patent number: 11390587
    Abstract: Improved methods for preparing chemical precursors to sulfonyl chloride III, which are important intermediates in the preparation of pyroxsulam herbicide are provided. Specifically, these precursors are compounds of Formulas VII and/or VIII, and IX, wherein R is a C1-C6 alkyl, R1 is a C1-C6 alkyl, X is Cl or OH, Y is halogen, OH, or OR2, and R2 is a C1-C6 alkyl.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 19, 2022
    Assignee: Corteva Agriscience LLC
    Inventors: Jossian Oppenheimer, Matthias S. Ober, Mark E. Ondari, Michael Gullo, Jayachandran Devaraj, Amaruka Hazari, Will Kruper
  • Patent number: 11390586
    Abstract: The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, and use of compounds of formula II or III, or salts thereof.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: July 19, 2022
    Inventors: Per Andrén, Luke Odell, Anna Nilsson, Mohammadreza Shariatgorji, Jonas Sävmarker
  • Patent number: 11390608
    Abstract: The present specification provides crystalline forms of 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one hydrochloride, methods of preparing the same, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: July 19, 2022
    Assignee: IDIENCE CO., LTD.
    Inventors: Kunhee Lee, Seoktaek Lee, Keuncheol Ryu, Hanna Seo, Hyeran Yang, Wonje Seong, Jinyoung Yoon
  • Patent number: 11390585
    Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: July 19, 2022
    Assignee: California Institute of Technology
    Inventors: Brian M. Stoltz, Scott C. Virgil, David E. White, Taiga Yurino, Yiyang Liu, Douglas C. Behenna, Douglas Duquette, Christian Eidamshaus
  • Patent number: 11384054
    Abstract: In certain aspects, the invention provides crystalline forms of ivacaftor N-(2,4-di-tert-butyl-phenyl-5-hydroxy-phenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. In related aspects, the invention provides a process for preparing any one of crystalline forms S2, S3, S4 and S5 of ivacaftor. The process includes: forming a solution including crude ivacaftor and a solvent; adding an anti-solvent to the solution to form slurry including a precipitate; isolating the precipitate; and drying the precipitate to provide crystalline form S2, S3, S4, or S5 of ivacaftor.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: July 12, 2022
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Kuan-Hsun Huang, Li-Ting Wang, Inze Lin, Tsung-Cheng Hu
  • Patent number: 11376234
    Abstract: A material which promotes ammonia metabolism in the body, as well as a material which has excellent ammonia metabolism improving effect and is effective for endurance enhancement and anti-fatigue are provided. An ammonia metabolism promoting agent, comprising catechins as an active ingredient. An agent for preventing or ameliorating hyperammonemia, hepatic encephalopathy or chronic fatigue syndrome, comprising catechins compound as an active ingredient. An ammonia metabolism promoting agent, an endurance enhancing agent and an anti-fatigue agent, comprising catechins, citrulline and arginine as active ingredients.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: July 5, 2022
    Assignee: Kao Corporation
    Inventors: Takahiro Hasumura, Shu Chen, Noriyasu Ota, Mizuki Tsunakawa, Yoshihiko Minegishi
  • Patent number: 11369113
    Abstract: The present inventions concerns use of a specific methoxyacrylate compound to control mosquitoes, and vector control products comprising that methoxyacrylate compound, in particular the invention relates to a substrate, to a composition, for controlling mosquitoes, and to a specific methoxyacrylate compound, processes for the synthesis of mosquitocidal methoxyacrylate compounds and new intermediates.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: June 28, 2022
    Assignee: Syngenta Participations AG
    Inventors: Ottmar Franz Hueter, Mark Hoppe, Tomas Smejkal, Raphael Dumeunier, Nicolas Fedou, Edouard Godineau, Philip Wege, Peter Maienfisch
  • Patent number: 11358964
    Abstract: The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 14, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventors: Andrew J. Norris, Sudip Chakrabortty
  • Patent number: 11358930
    Abstract: Selective potassium channel agonists and methods of use thereof are disclosed. A compound, or a pharmaceutically acceptable salt thereof, having a formula I wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted C1-C6 alkyl or optionally-substituted cyclopropyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, optionally-substituted alkyl, or R6 and R7 together form a carbocycle; R8 is substituted phenyl or optionally-substituted pyridinyl, provided that if R8 is substituted phenyl, then R2 is optionally-substituted cyclopropyl; and R9, R10 and R11 are each independently H, halo, or optionally-substituted alkyl.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 14, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Peter Wipf
  • Patent number: 11352336
    Abstract: Disclosed is a cost-effective process for catalytic conversion of simple C6-based sugars (such as glucose and fructose) and industrial-grade sugar syrups derived from starch (such as different grades of High Fructose Corn Syrup) and cellulosic biomass to 5-HydroxyMethylFurfural (5-HMF) in a continuous-flow tubular reactor in bi-phasic media using inexpensive heterogeneous solid catalysts. Commercial and synthesized heterogeneous solid catalysts were used and their activities in terms of sugar conversion and HMF selectivity and yield were compared. Continuous dehydration of fructose, glucose and industrial-grade sugar syrups derived from corn and wood to HMF was achieved and the stability of selected catalysts and feasibility of catalyst recycling and regeneration were demonstrated.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 7, 2022
    Assignee: THE UNIVERSITY OF WESTERN ONTARIO
    Inventors: Chunbao Xu, Sadra Souzanchi, Tirumala Venkateswara Rao Kasanneni, Zhongshun Yuan
  • Patent number: 11352350
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: June 7, 2022
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • Patent number: 11351175
    Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
    Type: Grant
    Filed: January 11, 2020
    Date of Patent: June 7, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11352367
    Abstract: Compounds of formula (I): wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: June 7, 2022
    Assignee: TARO PHARMACEUTICALS INC.
    Inventors: Curtis Harwig, Jeremy D. Pettigrew, Jennifer Cross, Jeyaprakashnarayanan Seenisamy, Mahesh Narayan Keregadde, Karthikeyan Iyanar
  • Patent number: 11339138
    Abstract: The present invention provides a method for preparing a compound of Formula C, Formula D, or Formula F: wherein each R1, R2, and R3 is independently H, SF5, N(C1-C8 alkyl)(C1-C8 alkyl), C(?S)N(C1-C8 alkyl)(C1-C8 alkyl), SO2N(C1-C8 alkyl)(C1-C8 alkyl), OSO2(C1-C8 alkyl), OSO2N(C1-C8 alkyl)(C1-C8 alkyl), N(C1-C8 alkyl)SO2(C1-C8 alkyl), or C1-C8 alkyl, C1-C8 haloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C10 cycloalkyl, C3-C10 halocycloalkyl, C4-C10 alkylcycloalkyl, C4-C10 cycloalkylalkyl, C6-C14 cycloalkylcycloalkyl, C5-C10 alkylcycloalkylalkyl, C3-C8 cycloalkenyl, C1-C8 alkoxy, C1-C8 haloalkoxy, C3-C8 cycloalkoxy, C3-C8 halocycloalkoxy, C4-C10 cycloalkylalkoxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C1-C8 alkylthio, C1-C8 alkylsulfinyl, C1-C8 alkylsulfonyl, C3-C8 cycloalkylthio, C3-C8 cycloalkylsulfinyl, C3-C8 cycloalkylsulfonyl, C4-C10 cycloalkylalkylthio, C4-C10 cycloalkylalkylsulfinyl, C4-C10 cycloalkylalkylsulfonyl, C2-C8 alkenylthio, C2-C8 alkenylsulfinyl, C2-C8 alkenylsulfonyl, C2-C8 alkynylthio, C2-C8 a
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 24, 2022
    Assignee: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Albert Loren Casalnuovo, Ty Wagerle, Jun Yan, Erin Demko, Matthew Richard Oberholzer, Rafael Shapiro